Short Summary
Maxell seeks director review of a PTAB final written decision that found all challenged claims of its fingerprint‑registration patent unpatentable. The patent owner argues the Board’s claim construction and obviousness analysis are erroneous and that the IPR should never have been instituted under §325(d).
Detailed Summary
In IPR2024‑00828, Maxell, Ltd. petitions the PTAB Director to vacate the final written decision that declared all twelve challenged claims of U.S. Patent 8,982,086 unpatentable. Maxell asserts that the Board misinterpreted the term “registering modes,” improperly applied prior‑art references (Rogers, Rosenberg, Bayram, Miyazawa), and ignored the patent’s extensive prior reexamination history, rendering the institution of the IPR contrary to 35 U.S.C. §325(d) and the Fintiv precedent. The petition emphasizes inconsistent expert testimony from Samsung and urges reversal of the decision and termination of the proceeding.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Samsung Electronics Co. Ltd. et al. vs Maxell, Ltd. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Tessell, Inc.vsNutanix, Inc.
Nutanix filed a request for director review, urging the PTAB to deny Tessell’s IPR on grounds of unfair dealing, settled expectations, and prior art already examined. The petition argues that the inventors are attempting to profit twice from the same invention.
Samsung Electronics Co., Ltd et al.vsSecure Wi-Fi LLC
Samsung has requested Director Review of four IPRs involving Secure Wi‑Fi’s patent. The PTAB has limited the patent owner’s response to five pages and barred new evidence. The Director’s decision on the review is pending.
Wella Operations US LLCvsOlaplex, Inc.
The USPTO Office issued a notice detailing multiple institution decisions across various IPR and PGR proceedings.
Imperative Care, Inc.vsInari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,554,005 B2 catheter aspiration patent after Imperative Care showed a reasonable likelihood of success on at least one claim. The review covers all 15 claims and four obviousness grounds involving Garrison, Schaffer, Hartley, and Eller references.
Google LLC et al.vsPegasus Wireless Innovation LLC
Google and other carriers filed a Request for Director Review after the PTAB denied institution of an IPR against patent 10,721,118. They contend the Board abused discretion, misapplied Fintiv factors, and retroactively changed policy, seeking a review of the denial.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.